Table 1.
Characteristics of treatment protocols
| Protocols | 87 | 8801 | 8802 | 8805 | 9101 | 9102 | 9501 – 9502 armA | 9502 armB | 2000 |
|---|---|---|---|---|---|---|---|---|---|
| PDN | 2500 | 1830 | 1830 | 150 | 2030 | 1970 | 1970 | 1620 | 1910 |
| VCR | 20.5 | 9 | 12 | 9 | 12 | 12 | 12 | 15 | 18 |
| DNM | 180 | 160 | 160 | - | 120 | 120 | - | 120 | 120 |
| MTX IT | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ | ٧ |
| L-ASP | 5400 | 80000 | 80000 | - | 80000 | 80000 | 120000 | 120000 | 80000 |
| 6-MP | 6000 | 29920 | 25900 | - | 5100 | 28920 | 27350 | 6710 | 6830 |
| MTX IV | 180 | 1540 | 1500 | 30 | 1488 | 1500 | 1488 | 1500 | 1500 |
| CPM | - | 2000 | 3000 | 1600 | 1000 | 3000 | 1000 | 3000 | 2500 |
| DESA | - | 189 | 249 | 300 | 249 | 249 | 261 | 297 | 409 |
| 6-TG | - | 900 | 900 | - | 840 | 840 | 780 | 780 | 780 |
| ARA-C | - | 600 | 600 | 900 | 600 | 1800 | 600 | 1600 | 600-1800 |
| IFO | - | - | - | 12000 | - | - | - | - | - |
| VM-26 | - | - | - | 600 | - | - | - | - | - |
| ADM | - | 60 | 120 | 150 | 120 | 120 | 120 | 120 | 60-120 |
| Num. patients exposed | 2 | 1 | 2 | 4 | 5 | 28 | 2 | 57 | 6 |
Legend: Drugs are expressed as cumulative dose (mg/mq). PDN, prednisolone; VCR, vincristine; DNM, daunorubicin; MTX, metotrexate; IT, intrathecal; ٧ included; L-ASP; L-asparaginase (UI/mq); 6-MP, 6-mercatopurine; IV, intravenously; CPM, cyclophosphamide; DESA, dexamethasone; 6-TG, 6-thioguanine; ARA-C, cytosine arabinoside.; IFO, ifosfamide; VM-26,teniposide; ADM, adriamycin.